Vicore Pharma Holding är ett läkemedelsbolag. Bolaget är verksamma inom forskning och utveckling av molekyler med agnostisk verkan på AT2 receptorn inom Renin Angiotensin System (RAS), som påverkar vätske- och saltbalansen i kroppen.

{{ eCtrl.event.layout.chapters.title || 'Select chapter' }}. {{ chapter.num }}. {{ chapter.name }}. {{ eCtrl.event.about.title }}. {{ lang.code }}.

Home/ Investors/ Press releases/ Press. Saknar releaseID-parameter Vicore Pharma’s offices. Kronhusgatan 11. 411 05 Göteborg, Sweden. Kornhamnstorg 53.

Vicore pharma press release

Gothenburg, February 9, 2021 – Vicore Pharma Holding AB (publ) (“Vicore Pharma” or the “Company”) today announces its intention to carry out a directed share issue corresponding to approximately SEK 300 million to institutional investors through an accelerated bookbuilding procedure (the “Directed New Share Issue”).

Göteborg, 2 november, 2020 - Vicore Pharma Holding AB (publ) ("Vicore"), som utvecklar innovativa läkemedel mot ovanliga lungsjukdomar, meddelar idag att bolaget förvärvat ett antal nya patenträttigheter som en del i framtagandet av nya angiotensin II typ 2 receptor (AT2R) agonister.

Press release from the extraordinary general meeting of Vicore Pharma Holding AB (publ) Approval of the board of directors’ resolution to issue shares The EGM resolved to approve the board of directors’ resolution to issue 11,200,000 shares at a subscription price of SEK 30.00 per share from 9 February 2021. VICORE PHARMA HOLDING AB (PUBL) : Press releases relating to VICORE PHARMA HOLDING AB (PUBL) Investor relations | NASDAQ OMX STOCKHOLM: VICO | NASDAQ OMX STOCKHOLM VICORE PHARMA HOLDING AB : Press releases relating to VICORE PHARMA HOLDING AB Investor relations | Nasdaq Stockholm: | Nasdaq Stockholm Vicore Pharma (publ) (ticker VICO) har publicerat en uppdaterad referenslista med de senaste publicerade studierna på läkemedelskandidaten C21. GOTHENBURG, Sweden, Feb. 9, 2021 /PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore Pharma" or the "Company") today announces its intention to carry out a directed share issue corresponding 2021-03-11 · GOTHENBURG, Sweden, March 11, 2021 /PRNewswire/ -- Vicore Pharma Holding AB (publ), a pharmaceutical company developing innovative medicines for severe lung disorders such as idiopathic pulmonary Vicore Pharma. VP02 is a partner carried out by Vicore Pharma based on Nanologica’s technology platform. The aim of the project is to develop a new drug for the treatment of Idiopathic Pulmonary Fibrosis (IPF), which is a deadly disease where the patients’ lung capacity gradually decreases due to fibrosis of the pulmonary tissue. vicore pharma holding ab (publ) press releases | nasdaq stockholm ab: vico | nasdaq stockholm ab Mölndal, 30 November 2018 – The Board of Directors of Vicore Pharma Holding AB (publ) (”Vicore Pharma”, or the ”Company”) has resolved, subject to the approval by an Extraordinary General Meeting (the “EGM”), on a directed issue of 9,414,706 new shares at a subscription price of SEK 17 per share.

Vicore Pharma Holding AB Carl-Johan Dalsgaard, CEO Tel: +46 70 975 98 63 E: carl-johan.dalsgaard@vicorepharma.com This information was submitted for …

Vicore Pharma AB (publ) (ticker: VICO) today announced that they strengthen the organization with three new key recruitments. Hans Jeppsson (Ph.D.) will be appointed Chief Financial Officer (CFO Stock release 05.03.2021 12:30 At the extraordinary general meeting (the "EGM") of Vicore Pharma Holding AB (publ) (the "Company") held on 5 March 2021, the below resolutions were mainly passed. Due to the extraordinary situation resulting from the COVID-19 pandemic the EGM was carried out through postal voting, without physical presence. 2020-04-01 Stock analysis for Vicore Pharma Holding AB (VICO:Stockholm) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Vicore Pharma gets regulatory approval to start phase II clinical trial with VP01 (C21) in patients with COVID-19, SARS CoV-2 infection. Gothenburg, April 28, 2020 – Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announces the….

Business news.

The board of directors of Vicore Pharma has, based on the issue authorisation granted by the annual general meeting on May 20, 2020 and as indicated in the Company's press release on July 2, 2020 Orphan Reach today announced that regulatory approval has been obtained for Vicore Pharma’s Phase II clinical trial with VP01 (C21) in patients with COVID-19, SARS CoV-2 infection. The board of directors of Vicore Pharma has, based on the issue authorisation granted by the annual general meeting on May 20, 2020 and as indicated in the Company’s press release on July 2, 2020, resolved on a directed share issue of 10,000,000 new shares at a subscription price of SEK 18.5 per share (the “Issue”), which means that the Company Press release from the extraordinary general meeting of Vicore Pharma Holding AB (publ) Publicerad: 2021-03-05 (Cision) Kommuniké från extra bolagsstämma i Vicore Pharma Holding AB (publ) The board of directors of Vicore Pharma has, based on the issue authorisation granted by the annual general meeting on May 20, 2020 and as indicated in the Company's press release on July 2, 2020 this press release does not constitute an offer to, or invitation to, acquire or subscribe for any financial instruments in vicore pharma in any jurisdiction. Gothenburg, July 2, 2020 – Vicore Pharma Holding AB (publ) (“Vicore Pharma” or the “Company”), today announces its intention to execute a directed share issue corresponding to approximately SEK 160 million to institutional investors. this press release does not constitute an offer to, or invitation to, acquire or subscribe for any financial instruments in vicore pharma in any jurisdiction. Gothenburg, July 2, 2020 - Vicore Pharma Holding AB (publ) ("Vicore Pharma" or the "Company"), today announces its intention to execute a directed share issue corresponding to approximately SEK 160 million to institutional investors. 2021-03-05 11:30:00 Press release from the extraordinary general meeting of Vicore Pharma Holding AB (publ)-3,38% | 4,16 MSEK 2021-02-26 09:00:00 Vicore Pharma Holding AB: Increase of number of shares and votes in Vicore Pharma +2,31% | 6,34 MSEK 2021-04-15 · Vicore Pharma publishes the Annual Report for 2020 - read this article along with other careers information, tips and advice on BioSpace Vicore Pharma Holding AB, a pharmaceutical company developing innovative medicines for severe lung disorders such as idiopathic pulmonary fibrosis, announced the publication of the Annual Report 2020.
Relationer socialpsykologi

Home/ Investors/ Press releases/ Press. Saknar releaseID-parameter Vicore Pharma’s offices.

Visionen är att etablera AT2-agonister som en ny och effektiv klass av läkemedel. Vicore Pharma AB (publ) (ticker: VICO) today announced that they strengthen the organization with three new key recruitments.
Privat dermatolog göteborg

lokförare utbildning krav
felaktig faktura radiotjänst
skivbolaget columbia 21 juni 1948
adm kalmar
vad ar sous chef
plattform malmö familjeteamet
logo rim caps

Press release from the extraordinary general meeting of Vicore Pharma Holding AB (publ) Publicerad: 2021-03-05 (Cision) Kommuniké från extra bolagsstämma i Vicore Pharma Holding AB (publ)

Göteborg, 10 februari 2021 - Vicore Pharma Holding AB (publ) (Vicore Pharma Clas Ohlson stämplas med sälj och Vicore Pharma med köp. måndagens förinspelade pressevenemang med en rad nyheter, rapporterar TT. Vicore Pharma publishes the Annual Report for 2020 Gothenburg, April 15, 2021 – Vicore Pharma Holding AB (publ), a pharmaceutical company developing innovative medicines for severe lung disorders such as idiopathic pulmonary fibrosis… Gothenburg, November 2, 2020 – Vicore Pharma Holding AB (publ) (“Vicore”), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announces the acquisition of a series of intellectual property rights (IPR) as part of the development of novel angiotensin II type 2 receptor (AT2R) agonists. Latest press releases 2021-04-15 Vicore Pharma publishes the Annual Report for 2020 2021-04-08 Notice of annual general meeting of Vicore Pharma Holding AB (publ) By Carl-Johan Dalsgaard, CEO of Vicore Pharma The rapid development, and now distribution, of COVID-19 vaccines is welcome progress in the global fight against this pervasive and mutating virus.

Senaste nytt om Vicore Pharma Holding aktie. Vicore Pharma Holding komplett bolagsfakta från DI.se.

Vicore Pharma Holding komplett bolagsfakta från DI.se. 2 Börsvärde (Market Cap) indikerar marknadsvärdet av valt aktieslag som är upptaget till handel på Nasdaq Nordic. Notera att bolaget kan ha ytterligare {{ eCtrl.event.layout.chapters.title || 'Select chapter' }}. {{ chapter.num }}. {{ chapter.name }}. {{ eCtrl.event.about.title }}. {{ lang.code }}.

vicore pharma holding ab (publ) press releases | nasdaq stockholm ab: vico | nasdaq stockholm ab Mölndal, 30 November 2018 – The Board of Directors of Vicore Pharma Holding AB (publ) (”Vicore Pharma”, or the ”Company”) has resolved, subject to the approval by an Extraordinary General Meeting (the “EGM”), on a directed issue of 9,414,706 new shares at a subscription price of SEK 17 per share.